


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**APPLICATION FOR CLINICAL TRIAL ON LM-364 “NECTIN-4^{TME} ADC” APPROVED
BY NMPA AND FDA**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that LM-364 “Nectin-4^{TME} ADC”, a national Category 1 innovative drug independently developed by LaNova Medicines Limited (“**LaNova Medicines**”), a wholly-owned subsidiary of the Group, has received clinical trial approval from China’s National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. In April this year, LM-364 also received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), and has officially commenced a clinical trial in Australia. The Group is accelerating the global clinical development of LM-364.

Nectin-4 is a clinically validated key ADC target that is highly expressed in various solid tumors, including urothelial carcinoma, triple-negative breast cancer, cervical cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma. However, conventional ADCs may bind not only to Nectin-4 expressed on tumor cells but also to Nectin-4 in normal tissues, potentially resulting in dose-limiting toxicities such as skin rash and neurotoxicity. These toxicities represent a major challenge in the clinical development of Nectin-4 targeted ADCs.

LM-364 is a next-generation Nectin-4 ADC developed by LaNova Medicines leveraging its proprietary tumor microenvironment (TME)-responsive antibody-drug conjugate (ADC) platform. It is specifically designed to mitigate both on-target and off-target toxicities commonly associated with conventional ADC therapies. Its design leverages the biological differences between the tumor microenvironment and normal tissues, enabling TME-dependent modulation of target binding, with high-affinity target binding selectively activated under tumor microenvironment conditions. Through this mechanism, LM-364 concentrates antitumor activity at the tumor site while minimizing normal tissue exposure, thereby offering a novel approach to mitigate toxicities associated with conventional Nectin-4 ADCs and potentially broadening the therapeutic window.

At the 2026 American Association for Cancer Research (AACR) Annual Meeting held in April, key preclinical study results for LM-364 were presented for the first time:

- Precise targeting and potent cytotoxicity: Under experimental conditions simulating specific tumor microenvironments, LM-364 demonstrated significantly enhanced target-binding capacity, as well as efficient endocytosis, potent and selective cytotoxicity against tumor cells, and a significant bystander effect, preliminarily validating its tumor microenvironment-responsive design.
- Broad-spectrum and potent in vivo antitumor activity: Significant tumor suppression was observed across multiple patient-derived xenograft (PDX) models. In particular, the tumor growth inhibition (TGI) rate reached 119.1% for triple-negative breast cancer, 107.46% for urothelial carcinoma, 168.79% for cervical cancer, and 86.73% for esophageal cancer.
- Safety: In 7-week repeat-dose toxicity studies in SD rats and rhesus monkeys, LM-364 was well tolerated, with a highest non-severely toxic dose (HNSTD) of 60 mg/kg in rhesus monkeys.

Following the approval of the clinical trial application, the Group will further evaluate the safety, tolerability, pharmacokinetic profile, and preliminary antitumor activity of LM-364 as a monotherapy and in combination therapy in patients with advanced solid tumors. The Group will also explore the recommended dose for subsequent clinical development, with the aim of providing safer and more effective treatment options for patients with advanced solid tumors.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 28 August 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.